Loading…
Employees: 1,519
Size Pulike Biological Engineering (603566.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $475M, the 3975th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥9.34 on 6 Nov 2026.
Performance Over six months the shares fell 22.0%, against -19.7% for the median peer and -16.4% for the China market (cap-weighted) — 8th lowest of 20 in its peer set.
Growth Revenue fell 9.0% over the last twelve months (peer median -4.9%); the operating margin is 5.1% (peer median 3.3%).
Valuation It trades at 21.0× forward earnings against a peer median of 11.1× (3rd most expensive of 6).
Price implies For today's price to make sense, revenue must grow about 6% a year for seven years (Req g). Recent delivered growth is +3%, so the hurdle is +2 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 1.6 points below its cost of capital (7.5% WACC).
Next results Next results expected around 23 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.00B | CN¥1.09B | CN¥1.04B | CN¥1.25B | CN¥1.23B |
| Revenue growth | — | +5% | -17% | +2% | — |
| Gross profit | CN¥627M | CN¥589M | CN¥570M | CN¥718M | CN¥729M |
| EBITDA | n/a | CN¥301M | CN¥226M | CN¥267M | CN¥247M |
| Net income | CN¥107M | CN¥185M | CN¥92.8M | CN¥175M | CN¥168M |
| Free cash flow | CN¥179M | CN¥295M | CN¥157M | CN¥4.23M | -CN¥103M |
| Capital expenditure | CN¥60.8M | CN¥75.0M | CN¥121M | CN¥305M | CN¥357M |
| Total debt | CN¥61.2M | CN¥62.9M | CN¥20.2M | CN¥37.1M | CN¥57.8M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 603566.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -8.2% | -11.3% | 8th highest of 20 |
| 6-month return | -22.0% | -19.7% | 8th lowest of 20 |
| Distance from 52-week high | -35.9% | -40.7% | 6th highest of 20 |
| Revenue growth (TTM) | -9.0% | -4.9% | 8th lowest of 21 |
| Operating margin | 5.1% | 3.3% | 8th highest of 21 |
| Forward P/E | 21.0× | 11.1× | 3rd most expensive of 6 |
| Growth the price implies (Req g, 7 yrs) | 5.7% | 7.1% | 6th least demanding of 12 |
| Growth delivered (Del g) | +3.3% | +0.7% | 3rd highest of 12 |
| Hurdle (Req g minus delivered) | +2.4 pp | +5.8 pp | 4th least demanding of 12 |
| ROIC minus cost of capital | -1.6 pp | -3.7 pp | 9th highest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Pulike Biological Engineering 603566.SS | China | $475M | -22% | -9% | 5% | 21.0× | 5.7% | +3.3% |
| Jiangsu Sihuan Bioengineering 000518.SZ | China | $476M | +7% | -17% | -28% | n/a | n/a | n/a |
| Hainan Shuangcheng Pharmaceuticals 002693.SZ | China | $476M | -10% | +40% | 13% | n/a | 44.5% | +1.0% |
| YungShin Global 3705.TW | Taiwan | $474M | +7% | -8% | 15% | n/a | -4.9% | +0.7% |
| Elixiron Immunotherapeutics (Cayman) 7871.TWO | Taiwan | $477M | +62% | +10,947% | -194% | n/a | n/a | n/a |
| CytomX Therapeutics CTMX | United States | $477M | -45% | -87% | -477% | n/a | n/a | n/a |
| Cachet Pharmaceutical 002462.SZ | China | $471M | -22% | -14% | 0% | n/a | -8.9% | -3.4% |
| Kexing Biopharm 688136.SS | China | $470M | -38% | -14% | -12% | 25.1× | n/a | n/a |
| Zhejiang Huakang Pharmaceutical 605077.SS | China | $470M | -39% | +35% | 4% | 11.1× | n/a | n/a |
| Alpha Teknova TKNO | United States | $482M | +104% | +12% | -35% | n/a | n/a | n/a |
| Shanghai Shenqi Pharmaceutical Investment Management 600613.SS | China | $483M | +9% | -4% | 3% | n/a | 13.4% | +1.4% |
| Harbin Medisan Pharmaceutical 002900.SZ | China | $467M | -13% | -5% | -29% | n/a | n/a | n/a |
| Tong Ren Tang Technologies 1666.HK | Hong Kong | $484M | -23% | -14% | 12% | 7.2× | -18.6% | +6.3% |
| Daewoong 003090.KS | South Korea | $485M | -29% | +5% | 11% | 4.1× | n/a | n/a |
| Evonile Pharma EVONILE.NS | India | $466M | n/a | -5% | 12% | n/a | 46.5% | -1.5% |
| Shaanxi Kanghui Pharmaceutical Co 603139.SS | China | $466M | -20% | -21% | -68% | n/a | n/a | n/a |
| Teyi Pharmaceutical 002728.SZ | China | $465M | -9% | -7% | 7% | 31.1× | 26.6% | +8.0% |
| Shanghai Jiaoda Onlly 600530.SS | China | $464M | -22% | -2% | -2% | n/a | 33.5% | -0.9% |
| Zhuhai Rundu Pharmaceutical 002923.SZ | China | $464M | -30% | +14% | 5% | n/a | 2.5% | -1.3% |
| Zhejiang Chengyi Pharmaceutical 603811.SS | China | $463M | -21% | +7% | 19% | n/a | 7.1% | +1.3% |
| PKU Healthcare 000788.SZ | China | $489M | -11% | -49% | 5% | n/a | -2.6% | -5.6% |